Deciphering metabolic rewiring in breast cancer subtypes (Q47836759)

6 February 2018

http://europepmc.org/abstract/MED/28774752

title

Deciphering metabolic rewiring in breast cancer subtypes (English)

1 reference

6 February 2018

http://europepmc.org/abstract/MED/28774752

author

Sophia Y Lunt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28774752 AND SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Martin P Ogrodzinski

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28774752 AND SRC:MED&resulttype=core&format=json

7 June 2020

Jamie J Bernard

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28774752 AND SRC:MED&resulttype=core&format=json

7 June 2020

publication date

15 July 2017

1 reference

6 February 2018

http://europepmc.org/abstract/MED/28774752

published in

Translational Research

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28774752 AND SRC:MED&resulttype=core&format=json

7 June 2020

volume

189

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28774752 AND SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

105-122

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28774752 AND SRC:MED&resulttype=core&format=json

Breast cancer incidence rates in U.S. women are no longer declining

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Cancer treatment and survivorship statistics, 2016.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Progress in adjuvant chemotherapy for breast cancer: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Understanding the Intersections between Metabolism and Cancer Biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Fundamentals of cancer metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The Emerging Hallmarks of Cancer Metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Cancer cell metabolism: one hallmark, many faces.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

In vivo cancer metabolism is defined by the nutrient microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Organ-Specific Cancer Metabolism and Its Potential for Therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Heterogeneity of tumor-induced gene expression changes in the human metabolic network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Brick by brick: metabolism and tumor cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Aerobic glycolysis: meeting the metabolic requirements of cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Mitochondria as biosynthetic factories for cancer proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metabolic control of signalling pathways and metabolic auto-regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Influence of metabolism on epigenetics and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Cancer Metabolomics and the Human Metabolome Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Emerging field of metabolomics: big promise for cancer biomarker identification and drug discovery.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Research into cancer metabolomics: Towards a clinical metamorphosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Clinical applications of metabolomics in oncology: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Monitoring cancer prognosis, diagnosis and treatment efficacy using metabolomics and lipidomics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Human plasma metabolomics for identifying differential metabolites and predicting molecular subtypes of breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Forecasting individual breast cancer risk using plasma metabolomics and biocontours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Plasma metabolomic profiles in breast cancer patients and healthy controls: by race and tumor receptor subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Oncometabolites: linking altered metabolism with cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

A roadmap for interpreting (13)C metabolite labeling patterns from cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

NMR-based Stable Isotope Resolved Metabolomics in systems biochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Application of metabolomics in drug resistant breast cancer research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Molecular portraits of human breast tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Repeated observation of breast tumor subtypes in independent gene expression data sets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The molecular portraits of breast tumors are conserved across microarray platforms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Supervised risk predictor of breast cancer based on intrinsic subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Triple-Negative Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metabolic phenotypes in triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

18F-fluorodeoxy-glucose positron emission tomography marks MYC-overexpressing human basal-like breast cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Expression of the hypoxia-inducible monocarboxylate transporter MCT4 is increased in triple negative breast cancer and correlates independently with clinical outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

An integrated genomic screen identifies LDHB as an essential gene for triple-negative breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

7 January 2021

MYC and Breast Cancer

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

c-Myc transactivation of LDH-A: implications for tumor metabolism and growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

MYC on the path to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glutamine addiction: a new therapeutic target in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glutamine and cancer: cell biology, physiology, and clinical opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glutaminolysis: A Hallmark of Cancer Metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glycolysis, glutaminolysis and cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Expression of glutamine metabolism-related proteins according to molecular subtype of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glutamine synthetase is a genetic determinant of cell type-specific glutamine independence in breast epithelia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glucose-dependent anaplerosis in cancer cells is required for cellular redox balance in the absence of glutamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Environment Impacts the Metabolic Dependencies of Ras-Driven Non-Small Cell Lung Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metabolic clusters of breast cancer in relation to gene- and protein expression subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metabolic characterization of triple negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Functional genomics reveal that the serine synthesis pathway is essential in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Expression levels of serine/glycine metabolism-related proteins in triple negative breast cancer tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Enhanced serine production by bone metastatic breast cancer cells stimulates osteoclastogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

cMyc-mediated activation of serine biosynthesis pathway is critical for cancer progression under nutrient deprivation conditions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The importance of serine metabolism in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Serine and glycine metabolism in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Nitric oxide and cancer: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Increased sensitivity of African American triple negative breast cancer cells to nitric oxide-induced mitochondria-mediated apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Pegylated arginase I: a potential therapeutic approach in T-ALL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Evidence for a stromal-epithelial "lactate shuttle" in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Comparative metabolomics of estrogen receptor positive and estrogen receptor negative breast cancer: alterations in glutamine and beta-alanine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The role of estrogen in the initiation of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Estrogen receptors: role in breast cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Estrogen modulates metabolic pathway adaptation to available glucose in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Low glucose dependent decrease of apoptosis and induction of autophagy in breast cancer MCF-7 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Estrogen Receptor α Promotes Breast Cancer by Reprogramming Choline Metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Interplay of choline metabolites and genes in patient-derived breast cancer xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Biological determinants of endocrine resistance in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Mechanisms of Endocrine Resistance in Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Cholesterol metabolism and resistance to tamoxifen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metabolomic profiling of hormone-dependent cancers: a bird's eye view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

AKT-induced tamoxifen resistance is overturned by RRM2 inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Trastuzumab: updated mechanisms of action and resistance in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Akt-dependent transformation: there is more to growth than just surviving

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2 breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Inflammatory breast cancer: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Inflammatory breast cancer: the disease, the biology, the treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

High incidence of HER-2 positivity in inflammatory breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

RhoC GTPase Is a Potent Regulator of Glutamine Metabolism and N-Acetylaspartate Production in Inflammatory Breast Cancer Cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Pyruvate kinase isoform expression alters nucleotide synthesis to impact cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Hallmarks of Cancer: The Next Generation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The angiogenic switch in carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Regulation of angiogenesis by hypoxia: role of the HIF system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Hypoxia-Inducible Factors: Master Regulators of Cancer Progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Hypoxia and breast cancer: prognostic and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Chemotherapy triggers HIF-1-dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

PHGDH Expression Is Required for Mitochondrial Redox Homeostasis, Breast Cancer Stem Cell Maintenance, and Lung Metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Estrogen regulation of anti-apoptotic Bcl-2 family member Mcl-1 expression in breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Trends in Obesity Among Adults in the United States, 2005 to 2014.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The Role of Body Mass Index in the Relative Risk of Developing Premenopausal versus Postmenopausal Breast Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Body size and risk of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Dual effects of weight and weight gain on breast cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Associations between energy balance and body mass index and risk of breast carcinoma in women from diverse racial and ethnic backgrounds in the U.S.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Adiposity, adult weight change, and postmenopausal breast cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Obesity and Cancer: The Oil that Feeds the Flame

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The impact of obesity on breast cancer: a retrospective review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Effect of obesity on prognosis after early-stage breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Adiposity and sex hormones in postmenopausal breast cancer survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Endogenous hormones and breast cancer risk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Endogenous steroid hormone concentrations and risk of breast cancer: does the association vary by a woman's predicted breast cancer risk?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Minireview: Obesity and breast cancer: the estrogen connection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Obesity as a risk factor for development and poor prognosis of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Adipocyte lipolysis links obesity to breast cancer growth: adipocyte-derived fatty acids drive breast cancer cell proliferation and migration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Hormone responsive human breast cancer in long-term tissue culture: effect of insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Molecular links between obesity and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Insulin resistance of amino acid and protein metabolism in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

TOR-centric view on insulin resistance and diabetic complications: perspective for endocrinologists and gerontologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Physiological consequences of ectopic agouti gene expression: the yellow obese mouse syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Pubertal and adult windows of susceptibility to a high animal fat diet in Trp53-null mammary tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Effect of high fat diet on body weight and mammary tumor latency in MMTV-TGF-alpha mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Diet-induced obesity and mammary tumor development in MMTV-neu female mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTV-TGF-alpha mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Adipocytes: impact on tumor growth and potential sites for therapeutic intervention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Adipocyte is a non-trivial, dynamic partner of breast cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Targeting cancer metabolism: a therapeutic window opens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

A history of cancer chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

5-Fluorouracil: mechanisms of action and clinical strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Chemotherapy-induced anemia in adults: incidence and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

[18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Changes in 2-fluoro-2-deoxy-D-glucose incorporation, hexokinase activity and lactate production by breast cancer cells responding to treatment with the anti-HER-2 antibody trastuzumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Natural fatty acid synthase inhibitors as potent therapeutic agents for cancers: A review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metformin and reduced risk of cancer in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

The cell-autonomous mechanisms underlying the activity of metformin as an anticancer drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Metformin Decouples Phospholipid Metabolism in Breast Cancer Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

Alterations in cellular energy metabolism associated with the antiproliferative effects of the ATM inhibitor KU-55933 and with metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.TRSL.2017.07.004

10.1016/J.TRSL.2017.07.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28774752 AND SRC:MED&resulttype=core&format=json

7 June 2020

1 reference